MDxHealth

IRVINE, CA, and LIEGE, BELGIUM -- (Marketwire) -- 02/18/13 -- MDxHealth SA (EURONEXT BRUSSELS: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support the diagnosis and treatment of cancer patients, today announced the results of two studies of the ConfirmMDx™ for Prostate Cancer test ... read more

IRVINE, CA, and LIEGE, BELGIUM -- (Marketwire) -- 02/11/13 -- MDxHealth SA (EURONEXT BRUSSELS: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support the diagnosis and treatment of cancer patients, today announced the publication of results from a large clinical study on its epigenetic ... read more

IRVINE, CA, and LIEGE, BELGIUM -- (Marketwire) -- 02/04/13 -- MDxHealth SA (EURONEXT BRUSSELS: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer diagnosis and treatment, today announced that Dr. Jan Groen, the Company's Chief Executive Officer, will present at the 15th Annual ... read more

IRVINE, CA, and LIEGE, BELGIUM -- (Marketwire) -- 11/30/12 -- MDxHealth SA (EURONEXT BRUSSELS: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced that it has joined forces with the Ghent University to establish NXTGNT, a new Center in Pharmaco ... read more

IRVINE, CA, and LIEGE, BELGIUM -- (Marketwire) -- 11/29/12 -- MDxHealth SA (EURONEXT BRUSSELS: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, currently listed on Euronext Brussels and Euronext Amsterdam, announced today that it will de-list from Euronext Amsterdam effective ... read more